EUVIMEDEUVIMED entdecken
Open Access

Extravasation Frequency of [ 177 Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients—A Single-Site Analysis

Gunjan Kayal, Finn Augensen, Lisa Bodei, Bae Chu, Harry Marquis, Lukas M Carter, John Humm, Adam L Kesner

Journal of Nuclear Medicine · 2025-08 · 66 (8) · 1258-1264

DOI: 10.2967/jnumed.124.269411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 26.06.2025. Verfasst von Gunjan Kayal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; and kayalg1@mskcc.org. Hauptthemen laut MEDLINE: Organometallic Compounds, Octreotide, Extravasation of Diagnostic and Therapeutic Materials, Radiopharmaceuticals. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extravasation of radiopharmaceuticals raises potential concerns, including adverse tissue reactions and reduction in both quantitative accuracy and therapeutic efficacy. This study presents a single-center experience reviewing extravasation events during [177Lu]Lu-DOTATATE administration in peptide receptor radionuclide therapy, assessing their frequency, impact on patient care, and dosimetric effects. Methods: [177Lu]Lu-DOTATATE was administered intravenously to outpatients following standard peptide receptor radionuclide therapy protocols. Whole-body planar imaging was performed 3-4 h after injection to confirm administration and assess extravasation, indicated by focal increased uptake at the infusion site. Qualitative image reviews by nuclear medicine physicians or technologists flagged potential extravasations. For these cases, regions of interest were delineated over the infused and contralateral arm and on the thighs. Extravasated activity was quantified relative to injected and whole-body activity. Absorbed dose calculations were performed using the MIRD formalism, assuming a monoexponential clearance model and accounting for varying extravasate volumes, with infiltration depths ranging from 2 to 7 mm. Statistical analyses compared retained activity and dosimetric parameters between extravasation and control groups.

Results

Among 1,314 administrations in 365 outpatients, 14 cases (1.1%) had increased uptake at the infusion site, suggesting extravasation. The maximum radiopharmaceutical retention at the infused site was less than 1% of total injected activity and less than 2.1% whole-body activity (accounting for bladder voiding). The corresponding extravasated activity related to administered activity was 0.07% and 0.01% in the extravasation and control groups, respectively (P < 0.001). The extravasation group had higher absorbed dose estimates at the infusion site than did the control group (median, 0.53 Gy [range, 0.12-1.23 Gy] vs. 0.32 Gy [range, 0.17-0.71 Gy]; P = 0.3), with a significantly higher median extravasated dose (0.14 Gy [range, 0.03-0.67 Gy] vs. 0.02 Gy [range, 0.0-0.19 Gy]; P < 0.001). We did not observe any radiogenic tissue reactions.

Conclusion

Extravasation during [177Lu]Lu-DOTATATE therapy was rare and resulted in minimal dosimetric consequences, with absorbed doses at the infusion site well below the thresholds for deterministic effects and soft-tissue necrosis. These findings indicate that extravasation had a negligible impact on treatment efficacy and patient safety in this patient cohort, reinforcing the safety of [177Lu]Lu-DOTATATE administration protocols and emphasizing the low clinical risk associated with radiopharmaceutical extravasation during therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Organometallic CompoundsOctreotideExtravasation of Diagnostic and Therapeutic MaterialsRadiopharmaceuticalsHumansMaleFemaleMiddle AgedAgedAdultRadiometryAged, 80 and over

Stichwörter der Autor:innen

[177Lu]Lu-DOTATATEextravasationinfiltrationradiopharmaceutical therapy

Substanzen

lutetium Lu 177 dotatateOrganometallic CompoundsOctreotideRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; and kayalg1@mskcc.org.
  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; and.
  • Molecular Imaging and Therapy, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.

Förderung

  • NCI NIH HHS

Zitieren

APA

Kayal, G., Augensen, F., Bodei, L., Chu, B., Marquis, H., Carter, L. M., Humm, J., & Kesner, A. L. (2025). Extravasation Frequency of [ 177 Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients—A Single-Site Analysis. Journal of Nuclear Medicine, 66(8), 1258-1264. https://doi.org/10.2967/jnumed.124.269411

Vancouver

Kayal G, Augensen F, Bodei L, Chu B, Marquis H, Carter LM, et al. Extravasation Frequency of [ 177 Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients—A Single-Site Analysis. Journal of Nuclear Medicine. 2025;66(8):1258-1264. doi:10.2967/jnumed.124.269411

BibTeX
@article{Kayal2025,
  author = {Kayal, Gunjan and Augensen, Finn and Bodei, Lisa and Chu, Bae and Marquis, Harry and Carter, Lukas M and Humm, John and Kesner, Adam L},
  title = {Extravasation Frequency of [ 177 Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients—A Single-Site Analysis},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {8},
  pages = {1258--1264},
  doi = {10.2967/jnumed.124.269411}
}
Kostenlos starten →